OGI - OrganiGram Holdings Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.47
-0.38 (-5.55%)
As of 3:24PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.85
Open6.78
Bid6.48 x 4000
Ask6.49 x 2200
Day's Range6.34 - 6.78
52 Week Range5.40 - 8.44
Volume1,236,565
Avg. Volume1,124,215
Market Cap1.005B
Beta (3Y Monthly)2.30
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Cannabis Stocks Worth Considering for Your Portfolio
    Motley Fool7 hours ago

    3 Cannabis Stocks Worth Considering for Your Portfolio

    MediPharm Labs, Canopy Growth, and OrganiGram get some love from three of our contributors who cover the marijuana space.

  • Organigram (OGI) Reported a Strong Quarter, But Don’t Buy the Stock Just Yet
    SmarterAnalyst22 hours ago

    Organigram (OGI) Reported a Strong Quarter, But Don’t Buy the Stock Just Yet

    With some cannabis industry players in disarray, Organigram (OGI) proved that a focus on reasonable operations is still the best path to rewarding shareholders.The stock has rallied over 17% this week following a solid FQ3’19 quarter and the company appears poised for more success. Whether or not the stock rallies back to previous highs near $8.50 is a far different story.Focused GrowthOrganigram is focused on domestic Canadian growth and the results are backing up this concept. The stock never got the wild valuations, but the FQ3 results are impressive considering that Canada isn’t producing the expected growth rates.The company saw FQ3 revenues dip to C$24.8 million from C$26.9 million or the equivalent of about $19.0 million. The numbers continue to suggest that demand in Canada is questionable due to the impacts of the thriving illegal market and lack of legal retail stores, but the company is thriving regardless.The reason the story works is that Organigram doesn’t need 10-fold production growth to meet operational costs. In the last quarter, the company only sold 3,926 kg of dried cannabis and 5,090 liters of oil.With only C$11.1 million in quarterly operating expenses, Organigram is able to overcome the cannabis market weakness from a lack of retail stores in Ontario and the delay in Cannabis 2.0 products. In addition, the focus on the right balance of production growth has cash costs under control during the ramp up phase.The company now has licensed capacity of 61,000 kg/yr with production capacity headed to 113,000 kg/yr by the end of 2019. With C$94.2 million in inventory, Organigram is taking the prudent move to reasonably expand production capability preparing the company for legitimate recreational cannabis growth in 2020.Positive EBITDA Instead of burning cash as the Canadian market slowly expands and chasing global markets not ready for commercialization, Organigram is focused on profitable growth. The company generated an incredible adjusted EBITDA profit of C$7.7 million in the last quarter or good enough for 30% EBITDA margins.The company is not focused purely on massive cultivation numbers and the results are paying off. The stock has a market valuation of ~$1 billion now so sales around $175 million for FY20 won’t offer much of a bargain for the stock in a sector where sentiment is frayed.Maintaining EBITDA margins in the 30%+ range will provide a boost to the stock as the year progresses. If FY20 EBITDA tops $50 million, the stock will eventually rally from higher EBITDA targets for FY21.TakeawayThe key investor takeaway is that Organigram Holdings is a prime example of prudent growth winning out in the end. The Canadian cannabis company has costs under control leaving the company not reliant on wild industry growth in order to survive and thrive like industry players with substantial EBITDA losses.Organigram likely outperforms the larger Canadian players with rich valuations, but the stock isn’t likely to see a big rally with the current negative sentiment in the sector. As cannabis-infused edibles and beverages hits the market at the end of 2019, the stock will likely offer a better entry point with a strong catalyst to rally than now.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here.Disclosure: No position. Read more: Does OrganiGram Rely Too Much on Recreational Cannabis?  More recent articles from Smarter Analyst: * This Analyst Doesn't See a Comeback in Netflix (NFLX) Stock Any Time Soon * There's Light at the End of the Tunnel for Canopy Growth (CGC) Stock, Analyst Says * Aurora Cannabis (ACB) Wins a 'Buy' for Rolling Up the Marijuana Industry * There's Light at the End of the Tunnel for Canopy Growth (CGC) Stock, Analyst Says

  • Zacksyesterday

    Trade Talk Cools Off Record-Setting Market

    Trade Talk Cools Off Record-Setting Market

  • 3 Reasons Linton’s Firing was Good News for Canopy Stock
    InvestorPlace2 days ago

    3 Reasons Linton’s Firing was Good News for Canopy Stock

    When it comes to the cannabis industry, the only real debate seems to be around how big it's going to get. Modest estimations put the industry at $40 billion by 2024. And there are few cannabis companies that catch the eye of investors quite like CGC stock.Source: Shutterstock But Canopy Growth (NYSE:CGC) hit a snag last week after it came out that the former CEO and co-founder Bruce Linton was fired. The company issued a press release saying that Linton has stepped down from his role as CEO and from the Board of Directors. Then in an interview with CNBC, Linton revealed that he was fired.Many investors were surprised to learn that Linton was let go, but this doesn't change the fundamentals of the company. Canopy Growth is still one of the most valuable cannabis stocks in Canada. Here are three reasons why Linton's firing was good news for CGC stock:InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Numbers Just Weren't ThereLinton did many things right during his run at Canopy. He secured a $4 billion investment from Constellation Brands (NYSE:STZ) and oversaw a number of important acquisitions. * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip However, when Constellation Brands made this investment, it earned a 37% stake in the company. It also earned the right to nominate four members to the six-member board. And when Canopy Growth reported losses of C$98 million during its fiscal fourth quarter, this hurt Constellation's bottom line as well. According to Constellation's fiscal first-quarter results, the company reported losses of $54.4 million tied to Canopy Growth. Going forward, Constellation Brands will likely find a replacement that is more interested in improving Canopy's bottom line. CGC Stock Is Ready for New LeadershipCanopy's recent financial performance probably had a lot to do with Linton's firing. But the company may also be looking to transition to new leadership, which isn't uncommon for a maturing company. After all, it takes a different skillset to build a company than it does to run a billion-dollar global brand. According to the press release, Mark Zekulin will act as sole CEO of the company while the board looks for outside leadership. This seems to indicate the company is looking for a new leader going forward, not Zekulin or another co-CEO. The company needs to prove it can find the right person to build on Canopy's momentum going forward. The Cannabis Industry Is ChangingLinton's firing will result in a major leadership change going forward. The change caught most investors off guard and the company's shares dropped roughly 5% that day. However, the stock quickly rebounded. After all, Linton is not the first CEO to be ousted from a cannabis company he founded. Aphria (NYSE:APHA), CannTrust Holdings (NYSE:CTST), and Organigram Holdings (NASDAQ:OGI) all replaced their original CEOs with more seasoned management.The cannabis industry as a whole is changing as it moves from its entrepreneurial beginnings to becoming a major consumer products industry. As the industry continues to change, investors will begin holding these companies to a different standard where profitability is the biggest determination of success. As of this writing, Jamie Johnson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post 3 Reasons Lintona€™s Firing was Good News for Canopy Stock appeared first on InvestorPlace.

  • Cultivation and Product Expansion Take Focus as OrganiGram Reports a Modest Third-Quarter Loss
    Motley Fool2 days ago

    Cultivation and Product Expansion Take Focus as OrganiGram Reports a Modest Third-Quarter Loss

    OrganiGram remains on track to complete its Moncton campus by year's end, and is eagerly awaiting the launch of derivative cannabis products in December.

  • Failed marijuana experiment slams Organigram earnings
    MarketWatch2 days ago

    Failed marijuana experiment slams Organigram earnings

    Organigram Holdings Inc. said Monday that growing marijuana cost it nearly 50% more in cash and harmed its earnings last quarter because the cannabis company tried — and failed — to develop a more efficient growing technique.

  • Organigram a Canadian Pot Rarity After Four Profitable Quarters
    Bloomberg2 days ago

    Organigram a Canadian Pot Rarity After Four Profitable Quarters

    (Bloomberg) -- With four quarters of profitability under its belt, Organigram Holdings Inc. is an anomaly in the Canadian cannabis market.Organigram has higher margins than most of its peers and one of the lowest costs per gram in the industry even though it grows indoors, generally considered the most expensive method of production. Chief Executive Officer Greg Engel attributes this to its ability to get higher yields from its pot plants than companies that grow in greenhouses, as well as its automated packaging lines.“We built a facility and designed a facility that was very focused on high-quality product because we felt there was a market opportunity that was sustainable,” Engel said in an interview at Bloomberg’s Toronto office.Organigram’s streak of profitability comes as the industry undergoes a period of significant upheaval. CannTrust Holdings Inc., previously considered one of the more reputable pot companies, plunged 48% last week after Canadian regulators said it grew cannabis in unlicensed areas of its greenhouse, forcing it to halt all sales and shipments of its products.That came less than a week after Canopy Growth Corp. fired co-CEO Bruce Linton amid shrinking margins and a C$323 million net loss in its most recent quarter.Lower ValuationMoncton, New Brunswick-based Organigram, meanwhile, reported its fourth consecutive quarter on Monday of positive adjusted earnings before interest, taxes, depreciation and amortization, or Ebitda. Revenue of C$25 million ($19 million) missed estimates and gross margin fell to 50% from 60% in the previous quarter, but Eight Capital analyst Graeme Kreindler said he views this as an “isolated event” related to a temporary change in cultivation protocols and the timing of shipments to provinces.Organigram said it cost 95 cents to produce a gram of dried flower in its most recent quarter. That was up from 65 cents in the previous quarter but still compares favorably with C$1.42 at Aurora Cannabis Inc. and $1.48 at Tilray Inc.No other large Canadian pot producer has managed to post such a long string of positive Ebitda. However, although it’s one of the best-performing pure-play pot stocks this year, up 64%, its valuation as measured by its price-to-sales ratio is well below those of its largest competitors.Engel is unperturbed. “At the end of the day, the worst thing that can happen to a company is you’ve got an artificial stock price that you can’t sustain,” Engel said.Competitors also spend a lot on stock promotion, he said. This “may in the short term be helping their stock price, but I’m not sure that’s sustainable without ongoing spending,” he said.The problems at CannTrust and Canopy signal a shakeout in an industry that’s still maturing nine months after Canada legalized recreational pot. Organigram is lucky because it had its wake-up call early, said Engel.The company had to recall several lots of its medical pot in late 2016 and early 2017 after it was found to contain an unapproved pesticide. Engel, who was CEO of Tilray Inc. at the time, was hired after the recall to “make a major cultural shift,” he said.“As a result of that recall, we had monthly ongoing inspections by regulators, and historically the industry was always complaining or defensive about the inspections,” Engel said. “My approach was to embrace them. At the end of the day it’s a partnership, not an adversarial relationship.”In the interview, Engel shared his views of the nascent industry:Beverages and EdiblesOrganigram isn’t being coy about its desire for a partner that can help it develop cannabis-infused beverages, similar to Constellation Brands Inc.’s investment in Canopy, Tilray’s partnership with Anheuser-Busch InBev SA or Hexo Corp.’s joint venture with Molson Coors Brewing Co.Organigram has developed a rapid-onset technology that will allow its drinks to take effect within 10 to 15 minutes, similar to alcohol, and has also created a flavorless cannabis powder that can be added to any beverage.“We wanted to go to these negotiations offering as much as possible,” Engel said. Organigram is seeking a partner from the alcohol industry that can help it develop beverages infused with THC, the cannabis compound that gets you high. It’s also seeking a consumer packaged goods partner for drinks infused with CBD, a non-intoxicating substance that’s thought to have health and wellness properties.BiosyntheticsEngel hopes Organigram’s investment in Montreal-based Hyasynth Biologicals Inc. will also help it lure a partner. Hyasynth is developing large-scale biosynthetic production of cannabinoids, or the active compounds found in cannabis. This method, which uses yeast to produce the compounds in a lab, is cheaper than extracting them from plants and will help lower production costs for products like beverages, edibles and vape pens, said Engel.U.S. Market“We’re very actively looking at the CBD market in the U.S.,” where the substance is legal at the federal level as long as it’s derived from hemp with very low THC content, Engel said. Organigram doesn’t plan to grow its own hemp but is looking at a range of possibilities, including investments in existing brands, products and companies.Corporate GovernanceOrganigram has a fully independent board of directors, a rarity in the cannabis sector. The CEO sees good corporate governance as essential to a well-run pot company.“This is an industry that’s still very much moving from founders and executives being chairmen or multiple insiders on boards, and I think some of the challenges we’ve seen in the industry have been because of a lack of governance,” he said. “You have to have independent governance that has oversight and holds management accountable.”To contact the reporter on this story: Kristine Owram in Toronto at kowram@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, ;David Scanlan at dscanlan@bloomberg.net, Jacqueline ThorpeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • After Hours: CBS and Viacom Apparently Set a Date, OrganiGram Nixes Experiment
    Motley Fool2 days ago

    After Hours: CBS and Viacom Apparently Set a Date, OrganiGram Nixes Experiment

    The looming merger in big entertainment seemingly has a deadline, and a big reason for a marijuana stock's quarterly loss is revealed.

  • Marijuana Stocks Rise Despite Organigram Loss; Aurora Cannabis Lands Cultivation Licenses
    Investor's Business Daily3 days ago

    Marijuana Stocks Rise Despite Organigram Loss; Aurora Cannabis Lands Cultivation Licenses

    Organigram earnings missed Q3 views. Aurora Cannabis got two new cultivation licenses. Organigram, Aurora and other marijuana stocks rose.

  • Barrons.com3 days ago

    OrganiGram Stock Rises Even as Cannabis Sales Fall

    The shortfall could reinforce worries about recreational marijuana demand in the year after Canada legalized such sales in October 2018.

  • Benzinga3 days ago

    Organigram Falls Despite Q3 Revenue Growth

    Cannabis company OrganiGram Holdings Inc. (NASDAQ: OGI) released its third-quarter financial report Monday morning. Organigram reported a quarterly net loss from continuing operations of CA$10.2 million or 7 cents per share on a diluted basis.. Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 -- Click here to learn more!

  • 10 Pure-Play Pot Stocks Forecast to Make Money in 2019
    Motley Fool3 days ago

    10 Pure-Play Pot Stocks Forecast to Make Money in 2019

    Despite supply and tax problems, some cannabis stocks are expected to make money this year.

  • MarketWatch3 days ago

    OrganiGram's stock turns lower after surprise loss, but revenue soars 7-fold

    The U.S.-listed shares of OrganiGram Holdings Inc. turned lower in premarket trading Monday, to a loss of 6.0% after being up as much as 2.4% earlier, after the Canada-based cannabis company reported a 7-fold increase in fiscal third-quarter net revenue but swung to a surprise loss amid fair value changes to biological assets in inventory. The company reported a net loss of C$10.2 million ($7.8 million), or 7 cents a share, after a profit of C$2.8 million, or 3 cents a share, in the year-ago period. Gross revenue increased nearly 9-fold to C$30.4 million, while net revenue including excise taxes rose to C$24.75 million ($19.0 million) from C$3.4 million. The FactSet consensus was for a profit of 3 cents and revenue of C$29.7 million. Cash and all-in-costs of cultivation increased to C$0.95 and C$1.29 per gram of dried flower, respectively, from C$0.65 and C$0.95 per gram in the sequential second quarter, due primarily to a "temporary" decrease in yield per plant resulting from a change in growing protocol. The company said yield returned to previous levels toward the end of the third quarter and into the fourth quarter. The stock has shed 8.3% over the past three months through Friday, while the ETFMG Alternative Harvest ETF has slid 13.1% and the S&P 500 has gained 3.7%.

  • Benzinga3 days ago

    The Week Ahead In Cannabis: Earnings, CannTrust Update And More

    Earnings reports, M&A deal updates and a potential update regarding CannTrust Holdings Inc (NYSE: CTST ) -- Here's what scheduled to take place this week in the cannabis industry. Organigram, Canopy Rivers ...

  • ACCESSWIRE3 days ago

    OrganiGram Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 15, 2019 / OrganiGram Holdings, Inc. (NASDAQ: OGI ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on July 15, 2019, 2018 at ...

  • Business Wire3 days ago

    Organigram Reports Third Quarter Fiscal 2019 Results

    MONCTON, New Brunswick-- -- Q3 and year to date 2019 1 net revenue of $24.8 million and $64.1 million, respectively, and Q3 net loss and net income from continuing operations of $10.2 million and $12.9 million, respectively Q3 and year to date gross margin, which includes the impact of fair value adjustments was and $59.5 million, respectively. Excluding the impact of non-cash fair value adjustments, ...

  • The 3 Most Profitable Marijuana Stocks You Can Buy Right Now
    Motley Fool4 days ago

    The 3 Most Profitable Marijuana Stocks You Can Buy Right Now

    Nearly all publicly traded cannabis companies are losing money at the moment, but not these three.

  • Organigram earnings: What to expect
    MarketWatch4 days ago

    Organigram earnings: What to expect

    CANNABIS WATCH Organigram Holdings Inc. is expected to report fiscal third-quarter earnings Monday before the opening bell. The company says it will host a conference call at 8 a.m. Eastern time. What to expect Earnings: On average, analysts polled by FactSet expect Organigram Holdings Inc.

  • Business Wire6 days ago

    Company Profile for Organigram Holdings Inc.

    Organigram Holdings Inc. is a NASDAQ Global Select and TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

  • This Major Marijuana Grower Reiterates Its Desire to Find a Beverage Partner
    Motley Fool7 days ago

    This Major Marijuana Grower Reiterates Its Desire to Find a Beverage Partner

    Three brand-name beverage companies could be the perfect partner for this Atlantic-based pot stock.

  • Benzinga8 days ago

    Organigram, Lift & Co. Collaborate On Educational Program

    Canada’s first branded cannabis oriented educational program is on its way, thanks to a newly announced collaboration between Organigram Holdings Inc. (NASDAQ: OGI) (TSX:OGI) and Lift & Co. Corp (TSXV:LIFT) (OTCQB: LFCOF). Organigram is concentrated on the production of high-quality, indoor-grown cannabis both for patients and adult recreational consumers. Among the company’s famous brands are Trailer Park Buds, The Edison Cannabis Company, and Ankr Organics.

  • Cannabis stocks dragged down by CannTrust’s losses after cannabis seizure
    MarketWatch8 days ago

    Cannabis stocks dragged down by CannTrust’s losses after cannabis seizure

    Cannabis stocks fell across the board Tuesday, led by CannTrust Holdings Inc. in a continued response to the news that the Canadian regulator has seized its cannabis after finding it was growing in unlicensed rooms.

  • Business Wire8 days ago

    Organigram and Lift & Co. Enhance Education of Cannabis Frontline Staff via Brand-Specific Training Program

    Organigram Holdings Inc. (OGI) (TSX VENTURE: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce a collaboration with Lift & Co. Corp ("Lift & Co.") (LIFT.V) (LFCOF) to support the launch of Canada’s first branded cannabis educational program via Lift & Co.’s CannSell retail training program.

  • Barrons.com9 days ago

    BMO Analyst Trims Outlook for Two Marijuana Stocks

    Faltering marijuana deliveries and regulatory troubles lead Tamy Chen to reconsider OrganiGram and CannTrust.

  • 3 Popular Pot Stocks That Had a Terrible June
    Motley Fool9 days ago

    3 Popular Pot Stocks That Had a Terrible June

    Having a brand name didn't save these marijuana stocks from a double-digit percentage decline.